• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
    • {%itemName%} {%arrowSpan%}
    • {%selfProduct%}
      • {%languages%}


      Our research in glaucoma has resulted in several successful introductions. Millions of patients with glaucoma all over the world use our medications to preserve their vision.1

      Our most common eye drops are Lumigan® (bimatoprost) and Ganfort® (bimatoprost + timolol). Lumigan is a prostaglandin analog administered as monotherapy. Ganfort is a combination drop that also includes a beta blocker, with a complementary mechanism of action.

      Preservative-free drops – for which patients?

      Treatment with preservative-free drops can be advantageous for certain patients.1–3 This pertains especially to patients switching from preservative-free treatment, patients who because of intolerance have problems with adherence, patients at high risk of needing surgical intervention and patients who have or are at risk of developing dry eye (OSD).

      Both Lumigan and Ganfort are available in a single dose without preservatives.



      What challenges are associated with eye drop treatment?
      Lack of adherence and difficulties associated with correct administration of eye drops by patients are common problems that may result in inadequate treatment effect and loss of vision.1–4 Other challenges for patients include the need for administration of several different drops, suffering from other diseases and/or age-related issues, such as memory problems.5–7

      Studies of patients who receive eye drop treatment for glaucoma show that:

      • Less than one third were able to administer a drop without the bottle touching the eye3
      • Among almost half of participants, the eye drop ended up on the eyelid or cheek4
      • More than a quarter of patients administered at least two drops instead of one4
      • Adherence to eye drop treatment for glaucoma was low (37%)8

      Ganfort® (bimatoprost+timolol) 0,3 mg/ml+5 mg/ml eye drops, solution, in multidose and single-dose container.

      Reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.2

      Lumigan® (bimatoprost) 0,1 mg/ml eye drops, solution, in multidose container and 0,3 mg/ml eye drops, solution, in single-dose container

      Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers).1

      When eye drop treatment does not work

      If the patient’s disease process progresses despite eye drop treatment, or if the patient has problems with the eye drop technique, tolerability, or adherence, surgical alternatives are also available.9

      Today’s surgical options are less invasive and easier to perform compared with traditional surgery. 


      Lorem ipsum.

      References: 1. XXX XXX